Literature DB >> 27580213

Efficient preparation of high-quality 64Cu for routine use.

Tomoyuki Ohya1, Kotaro Nagatsu2, Hisashi Suzuki1, Masami Fukada1, Katsuyuki Minegishi1, Masayuki Hanyu1, Toshimitsu Fukumura1, Ming-Rong Zhang1.   

Abstract

INTRODUCTION: Copper-64 is an attractive radionuclide for positron emission tomography and is emerging as a radiotherapeutic agent. The demand of 64Cu with low metallic impurities has increased because of its wide applications when incorporated with antibodies, peptides, and proteins. In this study, we propose a new separation method to produce high-quality 64Cu using a cation exchange column, as well as an automated separation system suitable for large-scale production.
METHODS: 64Cu was produced from an electrodeposited 64Ni target via the 64Ni(p,n)-reaction with a 24MeV HH+ beam at 10eμA (electrical microampere) conducted for 1-3h. The irradiated target was transported to a hot cell and disassembled remotely. 64Cu was separated by a solvent mixture of HCl and acetone on a cation-exchange resin, AG50W-X8. The chemical purity of 64Cu final product was evaluated using ion-chromatography coupled with a UV detector and inductively coupled plasma mass spectroscopy for quality as well as metallic impurities.
RESULTS: We obtained 64Cu in dried form at a yield of 5.2-13GBq at the end of separation, or 521±12MBq/eμAh as the final product within 2.5h of processing time. The metallic impurities were a satisfactory low level in the order of ppb. Major contaminants of Co and Ni were lower than those samples obtained by a widely accepted separation using an anion-exchange resin.
CONCLUSION: Using a cation-exchange resin and a systematic operation, we successfully reduced the contamination level of the 64Cu product. As a straightforward separation method, which shortened the entire processing time, we obtained a satisfactory amount of high-quality 64Cu available for routine use.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (64)Cu; Cation exchange column; Large scale production; Metallic contamination; Quality control; Remote control

Mesh:

Substances:

Year:  2016        PMID: 27580213     DOI: 10.1016/j.nucmedbio.2016.07.007

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer.

Authors:  Yukie Yoshii; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Yoko Oe; Ming-Rong Zhang; Kotaro Nagatsu; Aya Sugyo; Atsushi B Tsuji; Tatsuya Higashi
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

2.  Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer.

Authors:  Can Cui; Masayuki Hanyu; Akiko Hatori; Yiding Zhang; Lin Xie; Tomoya Ohya; Masami Fukada; Hisashi Suzuki; Kotaro Nagatsu; Cuiping Jiang; Rui Luo; Guoqiang Shao; Mingrong Zhang; Feng Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

Review 3.  Production of novel diagnostic radionuclides in small medical cyclotrons.

Authors:  Mateusz Adam Synowiecki; Lars Rutger Perk; J Frank W Nijsen
Journal:  EJNMMI Radiopharm Chem       Date:  2018-02-20

4.  Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts.

Authors:  Yukie Yoshii; Mitsuyoshi Yoshimoto; Hiroki Matsumoto; Hideaki Tashima; Yuma Iwao; Hiroyuki Takuwa; Eiji Yoshida; Hidekatsu Wakizaka; Taiga Yamaya; Ming-Rong Zhang; Aya Sugyo; Sayaka Hanadate; Atsushi B Tsuji; Tatsuya Higashi
Journal:  Oncotarget       Date:  2018-06-22

5.  64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts.

Authors:  Yukie Yoshii; Mitsuyoshi Yoshimoto; Hiroki Matsumoto; Takako Furukawa; Ming-Rong Zhang; Masayuki Inubushi; Atsushi B Tsuji; Yasuhisa Fujibayashi; Tatsuya Higashi; Tsuneo Saga
Journal:  Oncotarget       Date:  2017-09-28

6.  Establishing Reliable Cu-64 Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging.

Authors:  Qinghua Xie; Hua Zhu; Feng Wang; Xiangxi Meng; Qiushi Ren; Chuanqin Xia; Zhi Yang
Journal:  Molecules       Date:  2017-04-17       Impact factor: 4.411

7.  Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model.

Authors:  Zhao-Hui Jin; Atsushi B Tsuji; Mélissa Degardin; Aya Sugyo; Yukie Yoshii; Kotaro Nagatsu; Ming-Rong Zhang; Yasuhisa Fujibayashi; Pascal Dumy; Didier Boturyn; Tatsuya Higashi
Journal:  EJNMMI Res       Date:  2018-06-19       Impact factor: 3.138

8.  Multiple Administrations of 64Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts.

Authors:  Yukie Yoshii; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Ming-Rong Zhang; Yoko Oe; Hiroaki Kurihara; Yoshitaka Narita; Zhao-Hui Jin; Atsushi B Tsuji; Keiichiro Yoshinaga; Yasuhisa Fujibayashi; Tatsuya Higashi
Journal:  Transl Oncol       Date:  2017-11-17       Impact factor: 4.243

9.  Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer.

Authors:  Yukie Yoshii; Hideaki Tashima; Yuma Iwao; Eiji Yoshida; Hidekatsu Wakizaka; Go Akamatsu; Taiga Yamaya; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Chika Igarashi; Fukiko Hihara; Tomoko Tachibana; Ming-Rong Zhang; Kotaro Nagatsu; Aya Sugyo; Atsushi B Tsuji; Tatsuya Higashi
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

10.  Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography.

Authors:  Hiroki Matsumoto; Chika Igarashi; Tomoko Tachibana; Fukiko Hihara; Atsuo Waki; Ming-Rong Zhang; Sei Yoshida; Kenichiro Naito; Hiroaki Kurihara; Makoto Ueno; Kimiteru Ito; Tatsuya Higashi; Yukie Yoshii
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.